ERBB2 and breast cancer: HER2, overexpressed in 15%–20% of BC cases and associated with malignant proliferation (Giaquinto et al., 2022), undergoes ubiquitination and proteasomal degradation by Smurf1/2 (Gu et al., 2022; Ren et al., 2021).